IQ-AI Limited
(“IQ-AI” or the “Company”)
Imaging Biometrics Announces Channel Partnership
IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership continues IQ-AI’s strategy of making IB Clinic’s unique quantitative solutions accessible through widespread, global networks and marks the culmination of previously announced integration and validations efforts initiated in 2021.
Artificial intelligence (AI) marketplace platforms provide clinicians with a one-stop-shop for a wide array of medical imaging solutions. These platforms simplify and streamline access to proven tools, allowing clinicians to easily harness the exclusive capabilities that can benefit patients. IQ-AI intends to accelerate adoption of IB Clinic for healthcare providers through these global networks.
“Whilst it is too soon to predict the revenue impact of this new partnership, we are hopeful that it marks a significant expansion of availability globally,” said Trevor Brown, CEO of IQ-AI.
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com
The Directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
|
Tel: 020 7469 0930 |
|
Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 |
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).